Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA

Pat Gulhati, Yekaterina Y. Zaytseva, Joseph D. Valentino, Payton D. Stevens, Ji Tae Kim, Takehiko Sasazuki, Senji Shirasawa, Eun Y. Lee, Heidi L. Weiss, Jianli Dong, Tianyan Gao, B. Mark Evers

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Activation of phosphatidylinositol 3-kinase (PI3K)/Akt signaling is associated with tumorigenesis and metastasis of colorectal cancer (CRC). The mammalian target of rapamycin (mTOR) kinase, a downstream effector of PI3K/Akt signaling, regulates tumorigenesis and metastasis of CRCs, indicating that mTOR inhibition may have therapeutic potential. Notwithstanding, many cancers, including CRC, demonstrate resistance to the antitumorigenic effects of rapamycin. In this study, we show that inhibition of mTORC1 with rapamycin leads to feedback activation of PI3K/Akt and Ras-MAPK signaling, resulting in cell survival and possible contribution to rapamycin resistance. Combination with the multikinase inhibitor, sorafenib, abrogates rapamycin-induced activation of PI3K/Akt and Ras-MAPK signaling pathways. Combination of rapamycin with sorafenib synergistically inhibits proliferation of CRC cells. CRCs harboring coexistent KRAS and PIK3CA mutations are partially sensitive to either rapamycin or sorafenib monotherapy, but highly sensitive to combination treatment with rapamycin and sorafenib. Combination with sorafenib enhances therapeutic efficacy of rapamycin on induction of apoptosis and inhibition of cell-cycle progression, migration and invasion of CRCs. We demonstrate efficacy and safety of concomitant treatment with rapamycin and sorafenib at inhibiting growth of xenografts from CRC cells with coexistent mutations in KRAS and PIK3CA. The efficacy and tolerability of combined treatment with rapamycin and sorafenib provides rationale for use in treating CRC patients, particularly those with tumors harboring coexistent KRAS and PIK3CA mutations. Abbreviations: CIcombination index. CRCcolorectal cancer. IHCimmunohistochemistry. MAPKmitogen activated protein kinase. mTORmammalian target of rapamycin. PI3Kphosphatidylinositol 3-kinase.

Original languageEnglish (US)
Pages (from-to)1782-1790
Number of pages9
JournalCarcinogenesis
Volume33
Issue number9
DOIs
StatePublished - Sep 2012

Fingerprint

Sirolimus
Colorectal Neoplasms
Phosphatidylinositol 3-Kinase
Therapeutics
sorafenib
Mutation
Carcinogenesis
Phosphotransferases
Neoplasm Metastasis
Neoplasms
Heterografts
Protein Kinases
Cell Survival
Cell Cycle
Apoptosis

ASJC Scopus subject areas

  • Cancer Research

Cite this

Gulhati, P., Zaytseva, Y. Y., Valentino, J. D., Stevens, P. D., Kim, J. T., Sasazuki, T., ... Mark Evers, B. (2012). Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA. Carcinogenesis, 33(9), 1782-1790. https://doi.org/10.1093/carcin/bgs203

Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA. / Gulhati, Pat; Zaytseva, Yekaterina Y.; Valentino, Joseph D.; Stevens, Payton D.; Kim, Ji Tae; Sasazuki, Takehiko; Shirasawa, Senji; Lee, Eun Y.; Weiss, Heidi L.; Dong, Jianli; Gao, Tianyan; Mark Evers, B.

In: Carcinogenesis, Vol. 33, No. 9, 09.2012, p. 1782-1790.

Research output: Contribution to journalArticle

Gulhati, P, Zaytseva, YY, Valentino, JD, Stevens, PD, Kim, JT, Sasazuki, T, Shirasawa, S, Lee, EY, Weiss, HL, Dong, J, Gao, T & Mark Evers, B 2012, 'Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA', Carcinogenesis, vol. 33, no. 9, pp. 1782-1790. https://doi.org/10.1093/carcin/bgs203
Gulhati, Pat ; Zaytseva, Yekaterina Y. ; Valentino, Joseph D. ; Stevens, Payton D. ; Kim, Ji Tae ; Sasazuki, Takehiko ; Shirasawa, Senji ; Lee, Eun Y. ; Weiss, Heidi L. ; Dong, Jianli ; Gao, Tianyan ; Mark Evers, B. / Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA. In: Carcinogenesis. 2012 ; Vol. 33, No. 9. pp. 1782-1790.
@article{7695ba2246fa48fa9a0cd04f3583e2a1,
title = "Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA",
abstract = "Activation of phosphatidylinositol 3-kinase (PI3K)/Akt signaling is associated with tumorigenesis and metastasis of colorectal cancer (CRC). The mammalian target of rapamycin (mTOR) kinase, a downstream effector of PI3K/Akt signaling, regulates tumorigenesis and metastasis of CRCs, indicating that mTOR inhibition may have therapeutic potential. Notwithstanding, many cancers, including CRC, demonstrate resistance to the antitumorigenic effects of rapamycin. In this study, we show that inhibition of mTORC1 with rapamycin leads to feedback activation of PI3K/Akt and Ras-MAPK signaling, resulting in cell survival and possible contribution to rapamycin resistance. Combination with the multikinase inhibitor, sorafenib, abrogates rapamycin-induced activation of PI3K/Akt and Ras-MAPK signaling pathways. Combination of rapamycin with sorafenib synergistically inhibits proliferation of CRC cells. CRCs harboring coexistent KRAS and PIK3CA mutations are partially sensitive to either rapamycin or sorafenib monotherapy, but highly sensitive to combination treatment with rapamycin and sorafenib. Combination with sorafenib enhances therapeutic efficacy of rapamycin on induction of apoptosis and inhibition of cell-cycle progression, migration and invasion of CRCs. We demonstrate efficacy and safety of concomitant treatment with rapamycin and sorafenib at inhibiting growth of xenografts from CRC cells with coexistent mutations in KRAS and PIK3CA. The efficacy and tolerability of combined treatment with rapamycin and sorafenib provides rationale for use in treating CRC patients, particularly those with tumors harboring coexistent KRAS and PIK3CA mutations. Abbreviations: CIcombination index. CRCcolorectal cancer. IHCimmunohistochemistry. MAPKmitogen activated protein kinase. mTORmammalian target of rapamycin. PI3Kphosphatidylinositol 3-kinase.",
author = "Pat Gulhati and Zaytseva, {Yekaterina Y.} and Valentino, {Joseph D.} and Stevens, {Payton D.} and Kim, {Ji Tae} and Takehiko Sasazuki and Senji Shirasawa and Lee, {Eun Y.} and Weiss, {Heidi L.} and Jianli Dong and Tianyan Gao and {Mark Evers}, B.",
year = "2012",
month = "9",
doi = "10.1093/carcin/bgs203",
language = "English (US)",
volume = "33",
pages = "1782--1790",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA

AU - Gulhati, Pat

AU - Zaytseva, Yekaterina Y.

AU - Valentino, Joseph D.

AU - Stevens, Payton D.

AU - Kim, Ji Tae

AU - Sasazuki, Takehiko

AU - Shirasawa, Senji

AU - Lee, Eun Y.

AU - Weiss, Heidi L.

AU - Dong, Jianli

AU - Gao, Tianyan

AU - Mark Evers, B.

PY - 2012/9

Y1 - 2012/9

N2 - Activation of phosphatidylinositol 3-kinase (PI3K)/Akt signaling is associated with tumorigenesis and metastasis of colorectal cancer (CRC). The mammalian target of rapamycin (mTOR) kinase, a downstream effector of PI3K/Akt signaling, regulates tumorigenesis and metastasis of CRCs, indicating that mTOR inhibition may have therapeutic potential. Notwithstanding, many cancers, including CRC, demonstrate resistance to the antitumorigenic effects of rapamycin. In this study, we show that inhibition of mTORC1 with rapamycin leads to feedback activation of PI3K/Akt and Ras-MAPK signaling, resulting in cell survival and possible contribution to rapamycin resistance. Combination with the multikinase inhibitor, sorafenib, abrogates rapamycin-induced activation of PI3K/Akt and Ras-MAPK signaling pathways. Combination of rapamycin with sorafenib synergistically inhibits proliferation of CRC cells. CRCs harboring coexistent KRAS and PIK3CA mutations are partially sensitive to either rapamycin or sorafenib monotherapy, but highly sensitive to combination treatment with rapamycin and sorafenib. Combination with sorafenib enhances therapeutic efficacy of rapamycin on induction of apoptosis and inhibition of cell-cycle progression, migration and invasion of CRCs. We demonstrate efficacy and safety of concomitant treatment with rapamycin and sorafenib at inhibiting growth of xenografts from CRC cells with coexistent mutations in KRAS and PIK3CA. The efficacy and tolerability of combined treatment with rapamycin and sorafenib provides rationale for use in treating CRC patients, particularly those with tumors harboring coexistent KRAS and PIK3CA mutations. Abbreviations: CIcombination index. CRCcolorectal cancer. IHCimmunohistochemistry. MAPKmitogen activated protein kinase. mTORmammalian target of rapamycin. PI3Kphosphatidylinositol 3-kinase.

AB - Activation of phosphatidylinositol 3-kinase (PI3K)/Akt signaling is associated with tumorigenesis and metastasis of colorectal cancer (CRC). The mammalian target of rapamycin (mTOR) kinase, a downstream effector of PI3K/Akt signaling, regulates tumorigenesis and metastasis of CRCs, indicating that mTOR inhibition may have therapeutic potential. Notwithstanding, many cancers, including CRC, demonstrate resistance to the antitumorigenic effects of rapamycin. In this study, we show that inhibition of mTORC1 with rapamycin leads to feedback activation of PI3K/Akt and Ras-MAPK signaling, resulting in cell survival and possible contribution to rapamycin resistance. Combination with the multikinase inhibitor, sorafenib, abrogates rapamycin-induced activation of PI3K/Akt and Ras-MAPK signaling pathways. Combination of rapamycin with sorafenib synergistically inhibits proliferation of CRC cells. CRCs harboring coexistent KRAS and PIK3CA mutations are partially sensitive to either rapamycin or sorafenib monotherapy, but highly sensitive to combination treatment with rapamycin and sorafenib. Combination with sorafenib enhances therapeutic efficacy of rapamycin on induction of apoptosis and inhibition of cell-cycle progression, migration and invasion of CRCs. We demonstrate efficacy and safety of concomitant treatment with rapamycin and sorafenib at inhibiting growth of xenografts from CRC cells with coexistent mutations in KRAS and PIK3CA. The efficacy and tolerability of combined treatment with rapamycin and sorafenib provides rationale for use in treating CRC patients, particularly those with tumors harboring coexistent KRAS and PIK3CA mutations. Abbreviations: CIcombination index. CRCcolorectal cancer. IHCimmunohistochemistry. MAPKmitogen activated protein kinase. mTORmammalian target of rapamycin. PI3Kphosphatidylinositol 3-kinase.

UR - http://www.scopus.com/inward/record.url?scp=84865540541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865540541&partnerID=8YFLogxK

U2 - 10.1093/carcin/bgs203

DO - 10.1093/carcin/bgs203

M3 - Article

VL - 33

SP - 1782

EP - 1790

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 9

ER -